Skip to main content

Table 1 Clinical characteristics of Smokers and COPD groups, stratified by gender

From: Proteomic profiling of lung immune cells reveals dysregulation of phagocytotic pathways in female-dominated molecular COPD phenotype

  Male Female
  Smoker (n = 11) COPD (n = 10) p-value Smoker (n = 14) COPD (n = 8) p-value
GOLD (I/II) n.a. 4/6 n.a. n.a. 5/3b n.a.
GOLD (A/B) n.a. 8/2 n.a. n.a. 7/1b n.a.
Age 55.2 ± 6.0 56.9 ± 6.3 NS 57.1 ± 5.5 58.4 ± 3.9 NS
BAL macrophages [%] 95.7 ± 2.4 97.0 ± 1.4 NS 96.4 ± 2.5 95.1 ± 2.8 NS
BAL lymphocytes [%]a 2.3 (1.2, 5.4) 1.4 (0.2, 5.6) NS 1.7 (1, 7.2) 3.3 (1, 8.6) NS
BAL neutrophils [%]a 0.8 (0.2, 3.6) 0.8 (0, 1.6) NS 0.5 (0, 2.8) 0.5 (0.2, 1.4) NS
BAL eosinophils [%]a 0.0 (0, 1.4) 0.3 (0, 1.2) NS 0.1 (0, 1.2) 0.2 (0, 0.6) NS
BAL basophils [%]a 0.0 (0, 0.4) 0.0 (0, 0) NS 0.0 (0, 0.2) 0.0 (0, 0.2) NS
BAL mast cells/10 vis fieldsa 3(0.8) 3(0.6) NS 3(0.13) 1.5(0.20) NS
BMI 25.4 ± 2.8 25.1 ± 3.9 NS 24.8 ± 2.6 24.7 ± 4.2 NS
Packs/years 41.4 ± 18.8 42.3 ± 10.1 NS 37.6 ± 11.4 37.3 ± 9.4 NS
Cigarettes/day in last 6 months 19.4 ± 7.8 18.4 ± 5.2 NS 15.6 ± 5.8 14.9 ± 7.9 NS
FEV1 (% predicted) 104 ± 12.1 76.0 ± 8.0 < 0.01 107 ± 14.12c 81.5 ± 14b < 0.01
FEV1/FVC (% predicted) 77.3 ± 5.0 61.8 ± 6.6 < 0.01 77.4 ± 5.3c 58.8 ± 6.6b < 0.01
  1. Data are presented as mean ± SD tested by using t-test; or a, median (minimum, maximum) for skewed data, tested by Mann-Whitney U test; n.a., not applicable; NS, not significant (p > 0.05); b, no significant difference between male and female COPD patients (p > 0.30); c, no significant difference between male and female smokers (p > 0.70)